Applied Therapeutics (APLT) Operating Margin (2023 - 2025)
Historic Operating Margin for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to 1675.8%.
- Applied Therapeutics' Operating Margin rose 227037100.0% to 1675.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 9840.3%, marking a year-over-year decrease of 557527400.0%. This contributed to the annual value of 22922.86% for FY2024, which is 222770600.0% down from last year.
- According to the latest figures from Q3 2025, Applied Therapeutics' Operating Margin is 1675.8%, which was up 227037100.0% from 24379.51% recorded in Q3 2024.
- Over the past 5 years, Applied Therapeutics' Operating Margin peaked at 3149.63% during Q4 2023, and registered a low of 24379.51% during Q3 2024.
- Over the past 3 years, Applied Therapeutics' median Operating Margin value was 6111.15% (recorded in 2025), while the average stood at 7958.08%.
- Its Operating Margin has fluctuated over the past 5 years, first crashed by -104446400bps in 2024, then soared by 227037100bps in 2025.
- Applied Therapeutics' Operating Margin (Quarter) stood at 3149.63% in 2023, then crashed by -874bps to 24379.51% in 2024, then surged by 93bps to 1675.8% in 2025.
- Its last three reported values are 1675.8% in Q3 2025, 24379.51% for Q3 2024, and 14194.44% during Q2 2024.